207 related articles for article (PubMed ID: 23958394)
1. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
[TBL] [Abstract][Full Text] [Related]
2. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
3. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
4. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
5. Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy.
Wang Y; Wang Y; Zheng W
Int J Clin Exp Pathol; 2013; 6(10):2121-8. PubMed ID: 24133590
[TBL] [Abstract][Full Text] [Related]
6. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
Zhao L; Guo M; Sneige N; Gong Y
Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
[TBL] [Abstract][Full Text] [Related]
7. Tubal origin of 'ovarian' low-grade serous carcinoma.
Li J; Abushahin N; Pang S; Xiang L; Chambers SK; Fadare O; Kong B; Zheng W
Mod Pathol; 2011 Nov; 24(11):1488-99. PubMed ID: 21701538
[TBL] [Abstract][Full Text] [Related]
8. Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens.
Mhawech-Fauceglia P; Wang D; Menesses T; Chandavarkar U; Ough F; Lin Y; Liu S
Histopathology; 2012 May; 60(6):1019-20. PubMed ID: 22348438
[No Abstract] [Full Text] [Related]
9. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
10. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
11. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
12. Endosalpingiosis in peritoneal washings in women with benign gynecologic conditions: thirty-eight cases confirmed with paired box-8 immunohistochemical staining and correlation with surgical biopsy findings.
Sneige N; Dawlett MA; Kologinczak TL; Guo M
Cancer Cytopathol; 2013 Oct; 121(10):582-90. PubMed ID: 23674372
[TBL] [Abstract][Full Text] [Related]
13. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
[TBL] [Abstract][Full Text] [Related]
14. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
Tacha D; Zhou D; Cheng L
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions.
Wiseman W; Michael CW; Roh MH
Diagn Cytopathol; 2011 Sep; 39(9):651-6. PubMed ID: 20949455
[TBL] [Abstract][Full Text] [Related]
16. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
Fujiwara M; Taube J; Sharma M; McCalmont TH; Kim J
J Cutan Pathol; 2010 Sep; 37(9):938-43. PubMed ID: 20492080
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
18. Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
Park KJ; Patel P; Linkov I; Jotwani A; Kauff N; Pike MC
Histopathology; 2018 Apr; 72(5):766-776. PubMed ID: 29197096
[TBL] [Abstract][Full Text] [Related]
19. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cell blocks from effusion specimens in Gynecologic Oncopathology: An experience of 220 cases, diagnosed at a Tertiary Cancer Referral Center.
Rekhi B; Karmarkar S; Gupta C; Deodhar KK; Menon S; Pathuthara S; Maheshwari A; Shylasree TS; Gupta S
Indian J Pathol Microbiol; 2020; 63(3):427-434. PubMed ID: 32769333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]